Your session is about to expire
← Back to Search
Rucaparib for Ovarian Cancer (CATCH-R Trial)
CATCH-R Trial Summary
This trial is for patients who are already benefiting from the drug rucaparib and want to continue treatment. Patients from a related study can also enroll to continue collecting data.
- Ovarian Cancer
- Peritoneal Neoplasm
- Solid Tumors
- Prostate Cancer
CATCH-R Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 564 Patients • NCT01968213CATCH-R Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there other precedents for this Rucaparib research?
"Rucaparib was first studied in 2014 at Sourasky Medical Center. As of now, there are 15 completed studies and 35 active ones. A notable concentration of these active studies are based in Lakewood, Colorado."
Are people with the required medical conditions still able to join this experiment?
"Unfortunately, this particular study is not currently enrolling new patients. Although, it's worth mentioning that there are 766 clinical trials for carcinoma and 35 trials for Rucaparib currently recruiting patients."
Has Rucaparib been cleared by the FDA?
"There is pre-existing evidence suggesting that Rucaparib is safe for human use, so it was given a 3."
How many people have been or will be enrolled in this trial?
"Recruitment for this clinical trial has closed. The first posting was on March 22nd, 2021 with the most recent edit on January 18th, 2022. There are currently 766 other trials for carcinoma and 35 for Rucaparib that are admitting patients."
Does this city have more than one research center conducting this clinical trial?
"There are presently 6 sites running this trial, with locations in Lakewood, Sherbrooke, and London, amongst others. If you enroll in this trial, it is best to attend the site nearest you to avoid travel."
Has a similar study been done before?
"Rucaparib has had 35 clinical trials since the first one in 2014. The first, sponsored by Clovis Oncology, Inc., was a Phase 3 drug approval stage that involved 564 patients and completed in the same year. Since then, there have been 15 more completed trials."
Share this study with friends
Copy Link
Messenger